Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
Anna V. TinkerBC Cancer Agency, Vancouver Clinic, Vancouver, BC, Canada. [email protected]Susan EllardBC Cancer Agency, Centre for the Southern Interior, Kelowna, BC, CanadaStephen WelchLondon Regional Cancer Program, London, ON, CanadaFrancois MoensJuravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, CanadaGhassan AlloPrincess Margaret Hospital, University Health Network, Toronto, ON, CanadaMing‐Sound TsaoPrincess Margaret Hospital, University Health Network, Toronto, ON, CanadaJeremy A. SquireNCIC Clinical Trials Group, Queen's University, Kingston, ON, CanadaDongsheng TuNCIC Clinical Trials Group, Queen's University, Kingston, ON, CanadaElizabeth A. EisenhauerNCIC Clinical Trials Group, Queen's University, Kingston, ON, CanadaHelen MackayPrincess Margaret Hospital, University Health Network, Toronto, ON, Canada
2013en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references